QSAM Biosciences Inc., a company developing targeted therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (CycloSam®), for the treatment of cancer and related diseases, announced that the United States Patent & Trademark Office has granted a key patent protecting how CycloSam® is formulated and prepared, namely by using a nonradioactive kit that can be delivered and stored locally, close the administration site and provide for high purity in an efficient, facile and reproducible processing at lower costs.
This patent covers both the formulation and
preparation of CycloSam® in the U.S. with DOTMP kit formulations for
radioisotope delivery targeting bone tumors, as well the high-dosage use of the
radiopharmaceutical to perform bone marrow ablations. The scope of this patent is fairly broad in
that it not only protects the use of QSAM’s primary radioisotope, Samarium-153
(Sm-153), but also several other radioactive materials used in commercialized
radiopharmaceuticals such as Lutetium-177 (Lu-177) and Yttrium-90 (Y-90) in
conjunction with the chelating agent DOTMP. This patent provides the potential
to add additional radiopharmaceuticals to QSAM’s pipeline. The kit itself is
designed to provide convenient and reproducible preparation of the drug with
better delivery and higher purity for each specific formulation.
To
read more please visit:
Source: QSAM Biosciences